Navigation Links
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Date:5/7/2009

ing patients who have struggled unsuccessfully to lose weight for years."

The proportion of Qnexa patients losing 5 percent or more of their initial body weight was 66 percent for full-dose, 62 percent for mid-dose and 15 percent for placebo. The proportion of Qnexa patients losing 10 percent or more of their initial body weight was 41 percent for full-dose, 39 percent for mid-dose and 7 percent for placebo.

Qnexa was well-tolerated, with no drug-related serious adverse events in the study. The most common adverse events reported for the full-dose, mid-dose and placebo group were tingling (23%, 16%, 3%), dry mouth (18%, 13%, 0%), headache (16%, 15%, 13%), and constipation (15%, 7%, 8%). The completion rate for the study overall was 70 percent.

"The weight loss seen across our phase 2 and phase 3 obesity and diabetes Qnexa trials to date, coupled with the positive impact observed on other cardiometabolic factors such as blood pressure, cholesterol and glucose, is impressive and potentially represents a step forward in the treatment of obesity and obesity-related conditions," commented Leland Wilson, president and chief executive officer of VIVUS. "We are delighted to see these data - the first of our three phase 3 clinical trials evaluating Qnexa for obesity - highlighted at ECO."

In addition to EQUATE, the phase 3 Qnexa program includes two double-blind, placebo-controlled, multi-center studies that will compare Qnexa to placebo during a 56-week treatment period. The first year-long study, known as EQUIP (OB-302), enrolled morbidly obese patients with a Body Mass Index (BMI) of 35 or greater. The second year-long trial, known as CONQUER (OB-303), enrolled overweight and obese adult patients with BMIs from 27 to 45 and at least two co-morbid conditions, such as hypertension, dyslipidemia and type 2 diabetes. The co-primary endpoints for these studies are the mean percent weight loss and the per
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
2. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
3. Transcept Pharmaceuticals to Report First Quarter 2009 Results
4. Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
5. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
6. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
7. Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer
8. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
9. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
11. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... -- Burzynski Research Institute, Inc. (BRI) announced today that ... the company permission to conduct an open-label study of ... of age with a diffuse intrinsic brainstem glioma (DIPG). ... treatment groups based on their age and whether or ... primary study endpoint is a decrease in the size ...
(Date:10/22/2014)... , Oct. 22, 2014  Medical ... laboratory which specializes in high complexity, state-of-the-art, ... is now offering new Cystic Fibrosis Testing ... generation DNA sequencing platforms. Cystic ... inherited multisystem disorder that affects the respiratory, ...
(Date:10/22/2014)... MADISON, N.J. , Oct. 22, 2014  Quest ... provider of diagnostic information services, today announced that its ... Ph.D., to serve as a director, effective December 1, 2014. ... Dr. Leiden is the Chairman, President and CEO ... 20 years of scientific and commercial experience in the ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3
(Date:10/25/2014)... The Wehrman Collaborative, LLC (WeCo) ... disabled users by disabled users, has granted use ... Educational Resources of Burnsville, Minnesota, for their ... the Minnesota Alliance for Patient Safety of Minneapolis, ... website. Both organizations have met WeCo’s Standards ...
(Date:10/25/2014)... Everett, WA (PRWEB) October 25, 2014 ... their insulation has ‘gone bad’ need wonder no more. ... that homeowners should watch out for when it ... Bad insulation, according to the article released by Clean ... emphasize for homeowners that any insulation that has deteriorated, ...
(Date:10/25/2014)... Lyme, CT (PRWEB) October 25, 2014 ... an upcoming episode of Innovations with Ed Begley Jr, ... show times TBA. , In this episode, Innovations will ... solution helping to protect fragile, thinning skin on arms, ... Viewers will learn about these versatile products, which help ...
(Date:10/25/2014)... -- Not getting the right amount of sleep might ... suggests. Those who sleep less or more than ... be more prone to developing the chronic condition, which ... authors concluded that duration and quality of sleep are ... bowel diseases. "Both short and long durations of ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
Breaking Medicine News(10 mins):Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... Free ... Burrill & Co., BioAnalytics Group, ChanTest, GE Healthcare, Profectus Biosciences, Protagen, UNiConnect, and More ... Boston, MA ... online events for the healthcare, education and energy markets, and LabRoots , a ...
... Health Spending to Reach $1,318 per Person by 2018 ... report released today based on research by Emory ... Partnership to Fight Chronic Disease (PFCD), shows increasing obesity rates in ... care spending for states and individuals. The study, which was commissioned ...
... finds adults with records were more likely as tots to not ... are fearless at 3 years of age might just be poised ... poor fear conditioning at the tender age of 3 can ... other factors, such as education of the parents, large family size, ...
... ... Call Center , ... (PRWEB) November 17, 2009 -- VoiceNation, a leader in voicemail and ... powerful Customer Relationship software package. TASterix was chosen for its reliability, scalability and ...
... Richard ... civil damages award known in Berks County. The personal injury lawyer represented a ... Jurewicz negotiated with the Austrian manufacturer of the machine and won a settlement in ... ...
... ... manufacturer of support surface products for medical applications, introduces the ROHO Hybrid Elite cushion. ... DRY FLOATATION® with the stability of a Jay® contoured foam base engineered specifically for ... Belleville, ...
Cached Medicine News:Health News:BioConference Live Kicks-off Three Day Online Event for Life Science and Biotech Communities Today at 9:00 AM Eastern 2Health News:BioConference Live Kicks-off Three Day Online Event for Life Science and Biotech Communities Today at 9:00 AM Eastern 3Health News:Obesity Rates Will Continue to Increase, Drive Health Care Costs in New Jersey in Next Decade, According to New Study 2Health News:'Fearless' 3-Year-Olds Might Be Tomorrow's Criminals 2Health News:'Fearless' 3-Year-Olds Might Be Tomorrow's Criminals 3Health News:VoiceNation Calls on TASterix as Their CRM Solution 2Health News:Galfand Berger Personal Injury Lawyer Richard Jurewicz Obtains Record Recovery In Berks County 2Health News:The ROHO Group Introduces ROHO Hybrid Elite™ Two Trusted Brands; One Effective Cushion 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: